TOXICITY AND ANTICANCER ACTIVITY OF A NEW TRIAZINE ANTI-FOLATE (NSC-127755)
- 1 January 1982
- journal article
- research article
- Vol. 42 (5) , 1707-1715
Abstract
A new triazine folate antagonist, 3-chloro-4-[[4-[2-chloro-4-[4,6-diamino-2,2-dimethyl-s-triazin-1(2H)-yl]phenyl]butyl]] benzenesulfonyl fluoride compounded with ethanesulfonic acid (1:1) (NSC 127755), was highly active against 4 transplantable colon adenocarcinomas (36, 38, 10/A, 12/A) and the Dunning murine ovarian tumor M5076. Treatment schedule studies indicated that a prolonged time of exposure provided optimum antitumor activity for the compound. The combination of NSC 127755 plus 4-amino-1-[5-O-(1-oxohexadecyl)-.beta.-D-arabinofuranosyl]-2(1H)-pyrimidinone (palmO-ara-C, NSC 135962) had therapeutic synergism against grossly evident colon adenocarcinoma 36.This publication has 7 references indexed in Scilit:
- Affinity labeling of chicken liver dihydrofolate reductase by a substituted 4,6-diaminodihydrotriazine bearing a terminal sulfonyl fluoride.Journal of Biological Chemistry, 1981
- Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.Journal of Clinical Investigation, 1979
- DESIGN AND EVALUATION OF COMBINATION CHEMOTHERAPY TRIALS IN EXPERIMENTAL ANIMAL TUMOR SYSTEMS1979
- Antitumor Activity of Interferon Against Murine Osteogenic Sarcoma Cells In Vitro 2 3JNCI Journal of the National Cancer Institute, 1978
- BIOLOGY AND THERAPEUTIC RESPONSE OF A MOUSE MAMMARY ADENOCARCINOMA (16-C) AND ITS POTENTIAL AS A MODEL FOR SURGICAL ADJUVANT CHEMOTHERAPY1978
- COMBINATION CHEMOTHERAPY IN SEQUENCE FOR TREATMENT OF L1210-LEUKEMIA1978
- ESTROGEN-RECEPTOR CHARACTERIZATION IN A TRANSPLANTABLE MOUSE MAMMARY-TUMOR1977